News

The proceeds from this financing will be used for the advancement of Arcus’s clinical programs for AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody.

Sawai America is the parent company of US generics drugmaker Upsher-Smith Laboratories (USL). The deal allows Sawai and Sumitomo to form a strategic alliance in the generic pharmaceuticals

OI is a debilitating disease for which there is no current treatment approved by the U.S. Food and Drug Administration (FDA) or the EMA. Mereo announced commencement of

The sensor in Abilify MyCite is ingestible and can also record when the patients had taken the pill. Abilify MyCite has been approved for treating schizophrenia, acute treatment

This approval for Sprycel in pediatric patients with Ph+ CML in chronic phase was granted under priority review, and the indication received orphan drug designation from the FDA.

Woo-Yang Kim, Ph.D., associate professor, developmental neuroscience, led a team of researchers from UNMC and Creighton University into a deeper exploration of a genetic mutation that reduces the

ABP 215, which is a biosimilar to Avastin (bevacizumab), has been recommended for marketing authorization to treat certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for

The JV was formed in September 2012 by Pfizer with Zhejiang Hisun Pharmaceuticals (Hisun) with a total investment of $295m and a capital of $250m. Hisun will remain

PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). CMV is a